Amrutanjan Health Care Limited (AMRUTANJAN.BO)
INR 657.45
(-2.24%)
INR 657.45
(-2.24%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 449.72 Million INR | 12.9% |
| 2022 | 398.34 Million INR | -40.71% |
| 2021 | 671.88 Million INR | 9.8% |
| 2020 | 611.9 Million INR | 143.95% |
| 2019 | 250.83 Million INR | 2.32% |
| 2018 | 245.14 Million INR | 22.74% |
| 2017 | 199.73 Million INR | -8.38% |
| 2016 | 217.99 Million INR | -2.76% |
| 2015 | 224.17 Million INR | 50.42% |
| 2014 | 149.03 Million INR | 19.77% |
| 2013 | 124.43 Million INR | 23.0% |
| 2012 | 101.16 Million INR | 5.0% |
| 2011 | 96.35 Million INR | -5.65% |
| 2010 | 102.11 Million INR | -10.98% |
| 2009 | 114.71 Million INR | -87.58% |
| 2008 | 923.94 Million INR | 1737.96% |
| 2007 | 50.26 Million INR | -14.99% |
| 2006 | 59.13 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 46.15 Million INR | -66.21% |
| 2023 Q3 | 174.49 Million INR | 154.77% |
| 2023 Q1 | 70.14 Million INR | -44.74% |
| 2023 FY | 449.72 Million INR | 12.9% |
| 2023 Q2 | 68.49 Million INR | -2.36% |
| 2023 Q4 | 136.59 Million INR | -21.72% |
| 2022 Q4 | 126.95 Million INR | 18.53% |
| 2022 Q1 | 36.64 Million INR | -75.08% |
| 2022 Q2 | 127.65 Million INR | 248.39% |
| 2022 FY | 398.34 Million INR | -40.71% |
| 2022 Q3 | 107.1 Million INR | -16.09% |
| 2021 Q4 | 147.05 Million INR | -28.54% |
| 2021 FY | 671.88 Million INR | 9.8% |
| 2021 Q1 | 120.57 Million INR | 17.88% |
| 2021 Q2 | 198.47 Million INR | 64.61% |
| 2021 Q3 | 205.77 Million INR | 3.68% |
| 2020 Q1 | 64.27 Million INR | -18.56% |
| 2020 Q4 | 102.28 Million INR | -51.26% |
| 2020 Q3 | 209.85 Million INR | -10.88% |
| 2020 Q2 | 235.48 Million INR | 266.39% |
| 2020 FY | 611.9 Million INR | 143.95% |
| 2019 Q2 | 84.03 Million INR | 1292.31% |
| 2019 Q4 | 78.91 Million INR | -16.86% |
| 2019 Q3 | 94.92 Million INR | 12.96% |
| 2019 Q1 | -7.04 Million INR | -104.94% |
| 2019 FY | 250.83 Million INR | 2.32% |
| 2018 Q1 | -15.36 Million INR | -126.87% |
| 2018 FY | 245.14 Million INR | 22.74% |
| 2018 Q4 | 142.71 Million INR | 169.94% |
| 2018 Q3 | 52.86 Million INR | -18.57% |
| 2018 Q2 | 64.92 Million INR | 522.65% |
| 2017 Q2 | 93.37 Million INR | 718.14% |
| 2017 FY | 199.73 Million INR | -8.38% |
| 2017 Q3 | 64.33 Million INR | -31.1% |
| 2017 Q4 | 57.16 Million INR | -11.15% |
| 2017 Q1 | -15.1 Million INR | -157.48% |
| 2016 Q3 | 92.82 Million INR | 30.26% |
| 2016 Q2 | 71.26 Million INR | 0.0% |
| 2016 FY | 217.99 Million INR | -2.76% |
| 2016 Q4 | 26.27 Million INR | -71.69% |
| 2015 FY | 224.17 Million INR | 50.42% |
| 2014 FY | 149.03 Million INR | 19.77% |
| 2013 FY | 124.43 Million INR | 23.0% |
| 2012 Q2 | 32.12 Million INR | 956.71% |
| 2012 Q3 | 33.68 Million INR | 4.86% |
| 2012 Q4 | 32.31 Million INR | -4.06% |
| 2012 FY | 101.16 Million INR | 5.0% |
| 2012 Q1 | 3.04 Million INR | 0.0% |
| 2011 FY | 96.35 Million INR | -5.65% |
| 2010 FY | 102.11 Million INR | -10.98% |
| 2009 FY | 114.71 Million INR | -87.58% |
| 2008 FY | 923.94 Million INR | 1737.96% |
| 2007 FY | 50.26 Million INR | -14.99% |
| 2006 FY | 59.13 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Indoco Remedies Limited | 984.6 Million INR | 54.324% |
| Achyut Healthcare Limited | 5.73 Million INR | -7745.883% |
| Ajanta Pharma Limited | 8.16 Billion INR | 94.49% |
| Alkem Laboratories Limited | 17.95 Billion INR | 97.496% |
| Alpa Laboratories Limited | 167.76 Million INR | -168.069% |
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | 92.697% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | 72.155% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 98.583% |
| Bajaj HealthCare Limited | -837.93 Million INR | 153.671% |
| Bliss GVS Pharma Limited | 754.54 Million INR | 40.397% |
| Brooks Laboratories Limited | -195.91 Million INR | 329.547% |
| Lasa Supergenerics Limited | -217.3 Million INR | 306.955% |
| Lupin Limited | 19.14 Billion INR | 97.651% |
| Divi's Laboratories Limited | 16 Billion INR | 97.189% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 99.192% |
| Eris Lifesciences Limited | 3.91 Billion INR | 88.527% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 102.995% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | 90.449% |
| Granules India Limited | 4.05 Billion INR | 88.904% |
| Gufic Biosciences Limited | 861.35 Million INR | 47.789% |
| Hester Biosciences Limited | 188.89 Million INR | -138.089% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | 89.317% |
| Ipca Laboratories Limited | 5.47 Billion INR | 91.784% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | -100.207% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | 327.959% |
| Laurus Labs Limited | 1.6 Billion INR | 71.988% |
| Mankind Pharma Limited | 19.12 Billion INR | 97.649% |
| Medicamen Biotech Limited | 109.31 Million INR | -311.423% |
| Medico Remedies Limited | 82.9 Million INR | -442.433% |
| Megasoft Limited | -127.46 Million INR | 452.82% |
| NATCO Pharma Limited | 13.88 Billion INR | 96.761% |
| Procter & Gamble Health Limited | 2 Billion INR | 77.623% |
| Piramal Pharma Limited | 178.2 Million INR | -152.371% |
| RPG Life Sciences Limited | 876.6 Million INR | 48.697% |
| Sigachi Industries Limited | 571.8 Million INR | 21.349% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 111.614% |
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 99.53% |
| Syncom Formulations (India) Limited | 253.14 Million INR | -77.658% |
| Unichem Laboratories Limited | -704.74 Million INR | 163.814% |
| ZIM Laboratories Limited | 172.46 Million INR | -160.765% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 98.835% |
| Wanbury Limited | 559.56 Million INR | 19.629% |
| Windlas Biotech Limited | 581.87 Million INR | 22.71% |
| FDC Limited | 3.05 Billion INR | 85.266% |
| Suven Pharmaceuticals Limited | 3 Billion INR | 85.023% |
| Bal Pharma Limited | 73.92 Million INR | -508.379% |
| Strides Pharma Science Limited | -706.14 Million INR | 163.688% |
| Venus Remedies Limited | 284.9 Million INR | -57.85% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | 79.266% |
| Nectar Lifesciences Limited | 49.95 Million INR | -800.352% |
| Shilpa Medicare Limited | 318.74 Million INR | -41.094% |
| Aarti Drugs Limited | 1.71 Billion INR | 73.764% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | 66.546% |
| Suven Life Sciences Limited | -1.05 Billion INR | 142.8% |
| Ind-Swift Limited | 142.31 Million INR | -216.012% |
| Valiant Laboratories Limited | 3.19 Million INR | -13971.527% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | 91.862% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 107.926% |
| Themis Medicare Limited | 435.23 Million INR | -3.329% |
| Hikal Limited | 696.02 Million INR | 35.386% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 97.285% |
| Sequent Scientific Limited | -358.69 Million INR | 225.38% |
| Novartis India Limited | 851.9 Million INR | 47.209% |
| Wockhardt Limited | -4.63 Billion INR | 109.713% |
| Jubilant Pharmova Limited | 771 Million INR | 41.67% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | -6241.314% |
| Neuland Laboratories Limited | 3 Billion INR | 85.013% |
| Morepen Laboratories Limited | 961.59 Million INR | 53.231% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | -208.002% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | 595.746% |